Business Description
OncoTherapy Science Inc
ISIN : JP3202150003
Total Employee Number:
53Description
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan. The company is engaged in research and development of pharmaceuticals, large-scale analysis and testingof cancer genes, and research and development of cancer immunotherapy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.66 | |||||
Beneish M-Score | -3.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -25.2 | |||||
3-Year EBITDA Growth Rate | 21.9 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 10.3 | |||||
3-Year Book Growth Rate | 7.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.02 | |||||
9-Day RSI | 50.44 | |||||
14-Day RSI | 49.64 | |||||
3-1 Month Momentum % | -30.67 | |||||
6-1 Month Momentum % | -17.5 | |||||
12-1 Month Momentum % | -42.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.59 | |||||
Quick Ratio | 13.22 | |||||
Cash Ratio | 12.29 | |||||
Days Inventory | 35.7 | |||||
Days Sales Outstanding | 37.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.8 | |||||
Shareholder Yield % | -28.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 1.73 | |||||
Operating Margin % | -100.23 | |||||
Net Margin % | -112.63 | |||||
EBITDA Margin % | -112.2 | |||||
FCF Margin % | -122.24 | |||||
OCF Margin % | -114.35 | |||||
ROE % | -60.48 | |||||
ROA % | -50.13 | |||||
ROIC % | -600.79 | |||||
3-Year ROIIC % | -116.95 | |||||
ROC (Joel Greenblatt) % | -1794.84 | |||||
ROCE % | -57.49 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.16 | |||||
PB Ratio | 3.58 | |||||
Price-to-Tangible-Book | 4.13 | |||||
EV-to-EBIT | -6.49 | |||||
EV-to-EBITDA | -6.49 | |||||
EV-to-Revenue | 7.28 | |||||
EV-to-FCF | -5.97 | |||||
Price-to-GF-Value | 1.03 | |||||
Price-to-Median-PS-Value | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 4.13 | |||||
| Price-to-Net-Cash | 4.13 | |||||
Earnings Yield (Greenblatt) % | -15.41 | |||||
FCF Yield % | -12.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OncoTherapy Science Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4.542 | ||
| EPS (TTM) (€) | -0.016 | ||
| Beta | -0.5278 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 33.58 | ||
| 14-Day RSI | 49.64 | ||
| 14-Day ATR (€) | 0.004267 | ||
| 20-Day SMA (€) | 0.08075 | ||
| 12-1 Month Momentum % | -42.31 | ||
| 52-Week Range (€) | 0.064 - 0.194 | ||
| Shares Outstanding (Mil) | 398.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OncoTherapy Science Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OncoTherapy Science Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 3:1 Stock Split | 2004-09-27 | -- |
Show
Entries
OncoTherapy Science Inc Frequently Asked Questions
What is OncoTherapy Science Inc(FRA:30O)'s stock price today?
The current price of FRA:30O is €0.08. The 52 week high of FRA:30O is €0.19 and 52 week low is €0.06.
When is next earnings date of OncoTherapy Science Inc(FRA:30O)?
The next earnings date of OncoTherapy Science Inc(FRA:30O) is .
Does OncoTherapy Science Inc(FRA:30O) pay dividends? If so, how much?
OncoTherapy Science Inc(FRA:30O) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on OncoTherapy Science Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers